Hill-Rom Holdings
Market Cap
US$6.8b
Last Updated
2021/03/03 23:48 UTC
Data Sources
Company Financials +
Executive Summary
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Solid track record and good value.
Similar Companies
Share Price & News
How has Hill-Rom Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HRC is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: HRC's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
-4.5%
HRC
-3.1%
US Medical Equipment
-3.4%
US Market
1 Year Return
0.7%
HRC
28.0%
US Medical Equipment
29.4%
US Market
Return vs Industry: HRC underperformed the US Medical Equipment industry which returned 28% over the past year.
Return vs Market: HRC underperformed the US Market which returned 29.4% over the past year.
Shareholder returns
| HRC | Industry | Market | |
|---|---|---|---|
| 7 Day | -4.5% | -3.1% | -3.4% |
| 30 Day | 7.9% | -1.5% | 0.6% |
| 90 Day | 8.5% | 5.0% | 6.3% |
| 1 Year | 1.7%0.7% | 29.0%28.0% | 32.2%29.4% |
| 3 Year | 24.5%21.3% | 69.2%65.1% | 51.3%41.7% |
| 5 Year | 131.7%120.6% | 151.7%133.8% | 119.6%95.2% |
Long-Term Price Volatility Vs. Market
How volatile is Hill-Rom Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Here's What We Learned About The CEO Pay At Hill-Rom Holdings, Inc. (NYSE:HRC)2 weeks ago | Simply Wall St
Is There An Opportunity With Hill-Rom Holdings, Inc.'s (NYSE:HRC) 24% Undervaluation?1 month ago | Simply Wall St
Should You Rely On Hill-Rom Holdings's (NYSE:HRC) Earnings Growth?Valuation
Is Hill-Rom Holdings undervalued compared to its fair value and its price relative to the market?
25.2%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HRC ($103.15) is trading below our estimate of fair value ($137.93)
Significantly Below Fair Value: HRC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HRC is good value based on its PE Ratio (28.4x) compared to the US Medical Equipment industry average (51.7x).
PE vs Market: HRC is poor value based on its PE Ratio (28.4x) compared to the US market (21.4x).
Price to Earnings Growth Ratio
PEG Ratio: HRC is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: HRC is good value based on its PB Ratio (3.9x) compared to the US Medical Equipment industry average (5.2x).
Next Steps
Future Growth
How is Hill-Rom Holdings forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
15.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HRC's forecast earnings growth (15.7% per year) is above the savings rate (2%).
Earnings vs Market: HRC's earnings (15.7% per year) are forecast to grow slower than the US market (19.6% per year).
High Growth Earnings: HRC's earnings are forecast to grow, but not significantly.
Revenue vs Market: HRC's revenue (4% per year) is forecast to grow slower than the US market (10.1% per year).
High Growth Revenue: HRC's revenue (4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HRC's Return on Equity is forecast to be low in 3 years time (19.9%).
Next Steps
Past Performance
How has Hill-Rom Holdings performed over the past 5 years?
18.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HRC has high quality earnings.
Growing Profit Margin: HRC's current net profit margins (8.2%) are higher than last year (5.1%).
Past Earnings Growth Analysis
Earnings Trend: HRC's earnings have grown by 18.3% per year over the past 5 years.
Accelerating Growth: HRC's earnings growth over the past year (61.6%) exceeds its 5-year average (18.3% per year).
Earnings vs Industry: HRC earnings growth over the past year (61.6%) exceeded the Medical Equipment industry 9.8%.
Return on Equity
High ROE: HRC's Return on Equity (13.7%) is considered low.
Next Steps
Financial Health
How is Hill-Rom Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: HRC's short term assets ($1.3B) exceed its short term liabilities ($900.2M).
Long Term Liabilities: HRC's short term assets ($1.3B) do not cover its long term liabilities ($2.0B).
Debt to Equity History and Analysis
Debt Level: HRC's debt to equity ratio (103.8%) is considered high.
Reducing Debt: HRC's debt to equity ratio has reduced from 191.8% to 103.8% over the past 5 years.
Debt Coverage: HRC's debt is well covered by operating cash flow (27.6%).
Interest Coverage: HRC's interest payments on its debt are well covered by EBIT (5.9x coverage).
Balance Sheet
Next Steps
Dividend
What is Hill-Rom Holdings's current dividend yield, its reliability and sustainability?
0.85%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: HRC's dividend (0.85%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.31%).
High Dividend: HRC's dividend (0.85%) is low compared to the top 25% of dividend payers in the US market (3.69%).
Stability and Growth of Payments
Stable Dividend: HRC's dividends per share have been stable in the past 10 years.
Growing Dividend: HRC's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (24.2%), HRC's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: HRC's dividends in 3 years are forecast to be thoroughly covered by earnings (9.4% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.9yrs
Average management tenure
CEO
John Groetelaars (53 yo)
2.83yrs
Tenure
US$7,628,308
Compensation
Mr. John P. Groetelaars serves as President, Chief Executive Officer and Director of Hill-Rom Holdings Inc. since May 14, 2018. Mr. Groetelaars served in a variety of progressive roles at C.R. Bard during ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD7.63M) is about average for companies of similar size in the US market ($USD6.21M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.83yrs | US$7.63m | 0.025% $ 1.7m | |
| Senior VP & CFO | 2.25yrs | US$2.69m | 0.0096% $ 655.1k | |
| Senior VP | 5.17yrs | US$2.05m | 0.048% $ 3.3m | |
| Senior VP & President of Front Line Care business | 2.25yrs | US$2.17m | 0.025% $ 1.7m | |
| Senior VP & President of Patient Support Systems | 4.33yrs | US$2.57m | 0.0094% $ 641.4k | |
| Senior Vice President of Operations | 3.5yrs | no data | no data | |
| VP, Controller & CAO | 2.83yrs | no data | 0.0049% $ 333.4k | |
| CTO & Senior VP | 10.25yrs | no data | no data | |
| Chief Information Officer & Senior VP | 5.17yrs | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | 0.018% $ 1.2m | |
| Chief Compliance Officer | 6.33yrs | no data | no data | |
| Vice President of Corporate Communications | no data | no data | no data |
3.9yrs
Average Tenure
52yo
Average Age
Experienced Management: HRC's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.83yrs | US$7.63m | 0.025% $ 1.7m | |
| Independent Director | 11.25yrs | US$283.19k | 0.0030% $ 206.0k | |
| Independent Director | 13.67yrs | US$287.19k | 0% $ 0 | |
| Independent Chairman of the Board | 3yrs | US$397.12k | 0.0081% $ 554.5k | |
| Independent Director | 4yrs | US$294.19k | 0% $ 0 | |
| Independent Director | 3.42yrs | US$299.19k | 0% $ 0 | |
| Independent Director | 1.08yrs | US$244.97k | 0% $ 0 | |
| Independent Director | 8yrs | US$278.19k | 0% $ 0 | |
| Independent Director | 6yrs | US$275.19k | 0% $ 0 | |
| Independent Director | 4yrs | US$280.19k | 0.00045% $ 30.8k | |
| Independent Director | 1.83yrs | US$275.19k | 0% $ 0 |
4.0yrs
Average Tenure
62yo
Average Age
Experienced Board: HRC's board of directors are considered experienced (4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Hill-Rom Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Hill-Rom Holdings, Inc.
- Ticker: HRC
- Exchange: NYSE
- Founded: 1915
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$6.845b
- Shares outstanding: 66.36m
- Website: https://www.hillrom.com
Number of Employees
Location
- Hill-Rom Holdings, Inc.
- 130 East Randolph Street
- Suite 1000
- Chicago
- Illinois
- 60601
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| HRC | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jul 1971 |
| HB9 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 1971 |
Biography
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates through Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgica...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/03 23:48 |
| End of Day Share Price | 2021/03/03 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.